PTPN13 and metabolic dysfunction-associated steatohepatitis: Similarly, analysis of the FAP-1 levels demonstrated a 2.1 fold reduction in the HCV infected livers with fibrosis, 1.6 fold reductions in the NASH but showed no significant reduction in HCV infected liver with inflammation but no fibrosis when compared to control normal livers.